ABC | Volume 111, Nº6, December 2018

Original Article Radaelli et al Statin treatment in children: meta-analysis Arq Bras Cardiol. 2018; 111(6):810-821 Appendix I PuBMed Search Strategy #1. Search (Child OR Adolescent) #2. Search (HypercholesterolemiaOR StatinORDyslipidemias ORCholesterol OR Hydroxymethylglutaryl-CoA Reductase inhibitors) #3. Search (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation [mh] OR double- blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR (“clinical trial”[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR (“latin quare”[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative studies[mh] OR evaluation studies[mh]OR follow-upstudies[mh]ORprospectivestudies[mh]ORcross- over studies[mh] OR control* [tw] OR prospectiv*[tw] OR olunteer*[tw]) NOT (animal[mh] NOT human[mh]) #4. Search (#1 AND #2 AND #3) Appendix II Appendix 2 – Forest plots showing the effect of statin therapy on total cholesterol (TC) levels. 44 44 44 26 26 106 106 126 126 106 63 63 18 18 63 17 35 35 90 24 140 106 1424 1053 15 27 27 108 47 15 16 27 69 69 69 59 6 19 19 120 120 88 6 6 61 60 183.00 293.00 308.90 293.20 293.00 281.15 293.00 308.90 279.76 285.62 321.30 308.90 306.00 308.70 294.69 277.70 300.40 294.69 294.69 318.15 275.80 200.20 210.15 208.70 194.00 195.00 194.09 207.00 224.60 199.50 206.00 257.58 246.00 246.00 251.22 239.08 223.60 246.80 243.34 243.57 276.66 237.60 167.02 179.84 36.00 41.60 44.00 49.98 37.00 43.60 48.62 47.82 6.06 35.60 43.00 6.06 7.68 46.10 62.10 8.41 8.33 6.06 54.60 3.75 3.67 3.10 18.28 58.70 8.89 18.28 56.74 17.44 58.70 57.10 56.69 7.07 58.70 39.00 7.07 5.70 46.10 56.00 5.70 5.70 7.07 53.70 3.79 3.76 –110.00 –100.20 –99.20 –98.00 –87.06 –86.00 –84.30 –80.26 –79.62 –63.72 –62.90 –60.00 –57.48 –55.61 –54.10 –53.60 –51.35 –51.12 –41.49 –38.20 –33.18 –30.31 –66.41 4.6% 3.5% 4.5% 4.4% 4.4% 4.4% 4.5% 5.2% 3.6% 3.3% 4.8% 5.2% 5.1% 5.1% 5.1% 5.2% 5.2% 5.2% 3.7% 4.6% 3.5% 5.2% 100% [–124.10; –95.90] [–127.90; –72.50] [–101.79; –96.61] [–113.96; –82.04] [–103.48; –70.64] [–100.08; –71.92] [–112.07; –56.53] [–96.61; –63.91] [–95.80; –63.44] [–66.05; –61.39] [–88.93; –36.87] [–71.00; –49.00] [–59.82; –55.14] [–61.39; –49.83] [–79.85; –28.35] [–70.96; –36.24] [–57.41; –45.29] [–57.09; –45.15] [–43.81; –39.17] [–68.37; –8.03] [–34.12; –32.24] [–31.24; –29.38] [–75.52; –57.30] –100 100 –50 0 50 Avis 2010, Rosuvastatin 20 mg Avis 2010, Rosuvastatin 10 mg Avis 2010, Rosuvastatin 5 mg de Jongh 2002, Simvastatin 40 mg de Jongh 2002, Simvastatin 20 mg de Jongh 2002, Simvastatin 10 mg Stein 1999, Lovastatin 20 mg Stein 1999, Lovastatin 40 mg Stein 1999, Lovastatin 10 mg Knipscheer 1996, Pravastatin 20 mg Clauss 2005, Lovastatin 40 mg Clauss 2005, Lovastatin 20 mg Van der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg Van der Graff 2008, Simvastatin 10 mg–20 mg–40 mg/Ezetimibe 10 mg Rodenburg 2006, Pravastatin 40 mg Knipscheer 1996, Pravastatin 10 mg Knipscheer 1996, Pravastatin 5 mg Braamskamp 2015, Pitavastatin 4 mg Braamskamp 2015, Pitavastatin 2 mg Braamskamp 2015, Pitavastatin 1 mg Weigman 2004, Pitavastatin 20 mg–40 mg McCrindle 2003,Alorvastatin 10 mg–20 mg Heterogeneity: I-squared = 99.4%, tau-squared = 417, p < 0.0001 Random effects model Study Total Total SD SD Mean difference statins placebo Mean Mean MD W(random) 95%–Cl 819